Free Trial
NASDAQ:AIFF

Firefly Neuroscience 11/13/2023 Earnings Report

Firefly Neuroscience logo
$2.75 -0.09 (-3.17%)
Closing price 04:00 PM Eastern
Extended Trading
$2.76 +0.01 (+0.36%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Firefly Neuroscience EPS Results

Actual EPS
-$0.72
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Firefly Neuroscience Revenue Results

Actual Revenue
$1.97 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Firefly Neuroscience Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Firefly Neuroscience Earnings Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Firefly Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Firefly Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Firefly Neuroscience and other key companies, straight to your email.

About Firefly Neuroscience

Firefly Neuroscience (NASDAQ:AIFF) is a medical technology company focused on advancing brain health through objective digital biomarkers and remote monitoring solutions. Its flagship offering, the Firefly Brain Health Platform, combines portable electroencephalography (EEG) hardware, cloud-based signal processing and gamified cognitive assessments to enable early detection and ongoing tracking of neurological conditions. The company’s solutions are designed to provide clinicians, researchers and life sciences organizations with more sensitive and scalable tools for evaluating brain function outside of traditional lab settings.

At the heart of Firefly’s platform is a lightweight, user-friendly EEG headset that captures high-resolution brain signals during standardized cognitive tasks. Proprietary algorithms then analyze the data to generate quantitative metrics related to attention, memory, processing speed and neural connectivity. These digital biomarkers can be deployed in clinical trials to support endpoint assessments, as well as in outpatient and at-home environments to monitor treatment response, disease progression and recovery following injury or surgery.

Since its founding in 2017, Firefly Neuroscience has built partnerships with leading academic medical centers and pharmaceutical companies to validate its technology across a range of indications, including Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. The company is headquartered in Austin, Texas, with research and business development offices in the United States and Europe. Its platform is currently undergoing regulatory and clinical evaluations in multiple geographies, and pilot programs are underway with healthcare providers seeking more cost-effective, patient-centric approaches to neurological care.

The executive leadership team comprises seasoned entrepreneurs, neuroscientists and regulatory experts, led by founder and CEO Dr. Elaine K. Bearer, a neuroscientist with decades of research experience in neuroimaging. Firefly’s management brings together technical expertise in hardware design, software engineering and clinical operations, positioning the company to address growing demand for objective, data-driven solutions in brain health and digital neurology.

View Firefly Neuroscience Profile

More Earnings Resources from MarketBeat